and cerebral calcification (1). This CA isozyme, which was formerly called CA C, is normally widely distributed in man and has been identified (immunologically or by purification) in erythrocytes, brain, kidney, eye, cartilage, liver, lung, skeletal muscle, pancreas, gastric mucosa, and anterior pituitary body (2, 3) . The other CA isozymes, whose activities toward C02 and HC03-are lower than those of CA I1 in the order of CA II>CA IV>CA I>CA I11 (4-6), appear to have a more limited tissue distribution. CA I is found primarily in erythrocytes and CA I11 mainly in skeletal muscle (5) . CA IV differs from CA I, CA 11, and CA 111, the soluble cytosolic carbonic anhydrases, in being a membranebound glycoprotein and is found in the lung (4) . Identification of a quantitative defect in CA I1 in patients with this new inborn error of metabolism provides us with a unique opportunity to assess the importance and function of CA I1 in humans.
We report herein studies of the renal response to intravenously infused acetazolamide (a CA inhibitor) in CA 11-deficient patients. The renal response to infused acetazolamide in these patients is of great interest since CA I1 is the only soluble CA isozyme identified in the kidney (7) (8) (9) , and its absence apparently is responsible for the mixed or hybrid-type RTA in CA IIdeficient patients (10) (11) (12) (13) (14) (15) . However, there have been recent reports of a less well-characterized, membrane-bound luminal CA in the brush border of the proximal tubule of the kidney (1 6, 17) . The luminal CA appears to play an important role in the reclamation of filtered HC03-and is known to be sensitive to inhibition by acetazolamide (1 8, 19) . If the membrane-bound, luminal CA is the product of a different gene than CA 11, and if this gene is expressed normally in CA 11-deficient patients, infused acetazolamide would be expected to inhibit the luminal CA and produce an HC03-diuresis in CA 11-deficient patients. In the experiment described below, we compare the renal response to intravenous infusion of acetazolamide in two of the patients with CA I1 deficiency that we described previously (1, 11) with the responses of two control subjects.
METHODS
Experimental subjects. Two sisters (25 and 32 yr of age) homozygous for CA I1 deficiency (1) and two healthy men (22 and 24 yr of age) were studied. Urine acidification has been assessed previously in the CA 11-deficient sisters following the oral administration of 1.5 g of ammonium chloride four times daily for 3 days (1 1). The pH of their urine collected under oil (Radiometer pH meter) was 5.58 and 5.40 while the plasma pH was 7.17 and 7.12, respectively. These findings demonstrated a distal RTA. Although a low Tm for HC03-has been documented in other patients with this syndrome, studies to demonstrate this abnormality in these two patients were not successfully completed (1 1).
SLY E
None of the subjects was taking medication. The men were of comparable weights to the patients. Following informed consent, an aliquot was aspirated immediately from a timed urine collection into a 10-ml syringe and heparinized venous blood was collected without stasis into a 3-ml syringe. Syringes were immediately placed on ice. Each subject then received a single intravenous bolus of 125 mg of acetazolamide (Diamox, Lederle Laboratories, Division of American Cynamid Co., Pearl River, NY) dissolved in 1.25 ml normal saline, and the same studies were repeated at intervals during the subsequent 4-h period.
Biochemical studies were performed in the Clinical Chemistry Laboratory, Barnes Hospital, St. Louis, MO. Plasma and urine electrolytes (Na+, C1-, K+, total C02) were assayed with an Astra-8 automated analyzer (Beckman Instruments, Louisville, KY). Urine pH was determined with a Radiometer pH meter.
RESULTS
Results are summarized in Tables 1 and 2 . Basal venous pH and measured total C02 values in the patients with CA I1 deficiency (Table 1) were in keeping with their previously documented RTA (1, 1 1). Intravenous infusion of acetazolamide was well tolerated, both in patients and controls and was followed by a slight but progressive decrease in venous pH. Since the plasma HCO3-did not decrease, the acute decrease in pH following acetazolamide infusion must be entirely due to an increase in pC02. From data shown in Table 2 , it is clear that both the patients and controls demonstrated an abrupt increase in urine pH which was associated with increased urinary HC0,-excretion. Elevation of pH persisted even longer in patients than in controls. Urinary Na+/creatinine and K+/creatinine ratios both increased with the bicarbonaturia. However, the C1-Icreatinine ratio did not show a corresponding increase.
DISCUSSION
Two principal types of osteopetrosis have been described in man (20, 2 1). One is the dominantly inherited, relatively benign condition which is often detected radiologically in asymptomatic adults. A second type is the recessive, lethal, malignant form of osteopetrosis. This form is usually present at birth, becomes symptomatic early in infancy, and leads to death by early childhood from infection or bleeding. Since 1972, a number of families such as the one studied here have been reported with a recessively inherited syndrome of osteopetrosis with RTA and cerebral calcification (1 1-15) that is compatible with long survival. We recently presented evidence from studies in one kindred that a deficiency of CA I1 is the basic defect in this * Na+, K+, and C1-excretion are expressed as mmol/g creatinine. Pl and P2 are CA 11-deficient patients 111-1 and 111-6 from the family we reported previously (I), and C1 and C2 are control subjects BG and PL.
syndrome. We have since extended this finding to many other similarly affected families (22, 30) . The renal abnormalities in this syndrome are still incompletely understood. Most patients reported have a mixed or hybrid-type RTA (10) (11) (12) (13) (14) (15) . A proximal component was suggested by HC03-wasting at normal plasma concentrations (i.e. a low Tm for HC03-) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . A distal defect, profound in some patients, was evident from their inadequate ability to acidify their urine, even while quite acidotic
CA I1 is normally present in both proximal and distal tubules (9, 23). Lonnerholm (23) recently compared histochemical and immunohistochemical staining of human kidney preparations and confirmed the earlier findings of Spicer et al. (9) that the distal tubule and the collecting duct have a more intense immunohistochemical reaction for CA I1 than the moderate to light staining found in the cytoplasm of cells in the proximal tubule. Lonnerholm also found that the CA in the brush border of the proximal tubule (the luminal or membrane-bound CA) stains histochemically, but does not react with antisera to either CA I1 or CA I. Lack of cross-reactivity could result from failure of the histochemical reagents to get access to CA I or CA I1 in membranes. However, when this observation is taken together with the evidence that the luminal enzyme is an integral membrane glycoprotein and much larger than the soluble isozymes (53K versus 29K) (24) , the more likely interpretation is that the luminal enzyme is immunologically distinct and the product of a different gene than that which specifies CA 11.
We have no direct evidence on the status of CA I1 in the kidney of patients with the syndrome of osteopetrosis with RTA and cerebral calcification. Recent studies of CA activity in whole PC BM Lumen PC BM Lumen , and is exposed to cytosolic CA I1 which catalyzes its rehydration to form HC03-and H+. The HCO3-is transported from the contraluminal surface of the proximal tubular cell (probably in exchange for C1-) and the H+ generated by CA I1 is secreted in exchange for Na+ to initiate another cycle of HCO3-reabsorption. Loss of CA 11-mediated regeneration of H+ is suggested as the cause of HC03-wasting in CA 11-deficient patients. B, proposed role of CA I1 in distal urinary acidification. We propose that H+ is secreted into the lumen by a proton = translocating Mg++ ATPase, as in amphibians, which produces OH-in the cytosol. COs can condense with OH-to form HCOs-in a CA 11-catalyzed reaction, and HC03-can be transported across the basement membrane and into the peritubular capillary. We suggest that failure to titrate the OH-limits the ability to secrete H+ and acidify the urine appropriately in CA 11-deficient patients.
erythrocytes from the two patients described herein, using a "0-exchange method, demonstrated 55% of normal CA activity. This activity was attributed to the CA I isozyme, which is not diminished in these patients (22) . These studies suggest that the CA 11-deficient erythrocytes are not functionally impaired in C02 transport in vivo. Thus, the RTA is more likely to be the direct result of a deficiency of the CA I1 isozymes in the kidneys than a secondary consequence of CA I1 deficiency in erythrocytes.
In Figure 1 we present a model which can explain both the renal abnormalities in CA 11-deficient patients and their positive response to acetazolamide. In this model both the luminal (membrane-bound) CA and the soluble, cytosolic CA contribute to HC03-reabsorption in the proximal tubule in normal subjects (Fig. 1A) . Studies with CA inhibitors proved that enzymatic conversion of HC03-to COz is normally crucial for HC03-reabsorption by the proximal tubule (25) . That the CAs act at different sites and in different ways was suggested by experiments of Lucci et al. (19) . When the luminal enzyme was selectively inhibited, more than 80% of the HCO3-reabsorption by proximal tubule was blocked (18, 19) . Inhibition of the cytosolic enzyme, in addition, did not further inhibit HCO3-reabsorption, although it did reduce H+ secretion into the proximal tubule (19) . There is widespread agreement that HCO3-reabsorption depends on secretion of hydrogen ions (25) (26) (27) , and that an acetazolamide-sensitive intracellular CA plays a role in generating H+ for HC03-reclamation (19, 16) . Since CA I1 is the only soluble CA in kidney (7-9, 23, 24), we attribute this function to CA 11. We suggest that it is loss of the ability to regenerate H+ enzymatically which explains the impaired reabsorption of HC03-in CA 11-deficient patients. Such patients can waste up to 25% of the filtered load of HC03-when their HC03-concentrations are raised to normal levels by infusion ( 12-1 5) . However, HC03-wasting is not seen when patients are severely acidotic, suggesting that reabsorption of low filtered loads of HC03-does not require CA 11.
Most Ca 11-deficient patients are unable to acidify their urine appropriately when acidotic, suggesting a role for CA I1 in distal acidification as well. Immunohistochemical evidence indicates that certain cells of the distal tubule and the collecting ducts of the human kidney are "CA r i c h like their possible analogs in amphibians (9, 23) . In the turtle bladder, these specialized cells secrete H+ through a proton-translocating Mg++ATPase, and are capable of generating a steep pH gradient (28, 29) . The CA rich cells are sensitive to acetazolamide, possibly because CA is needed to titrate the OH-produced in the cytosol by the protontranslocating Mgf+-ATPase. In the model presented (Fig. 1 B) , we suggest a similar role for CA I1 in the distal tubules and collecting ducts of the human kidney. Such a role for CA I1 could explain the distal defect reported in many CA 11-deficient patients.
An experiment related to that reported herein was reported by
Guibaud et al. (12) in 1972. When they observed a response to acetazolamide indicating an acetazolamide-sensitive CA in kidney in their patients with this syndrome, they concluded that CA deficiency must now be the basis of their osteopetrosis with RTA. These observations must now be reinterpreted. We recently collaborated with Professor Guibaud to measure CA I1 levels in erythrocytes from his patients and found in them the same profound deficiency of CA I1 (22) that we reported earlier (1) in the two sisters studies in this report. We propose that in his patients as in our patients, the bicarbonaturia following acetazolamide can be explained by inhibition of the luminal carbonic anhydrase which is not affected by the mutation which produces the CA I1 deficiency syndrome.
